Status:

COMPLETED

Exercise-Induced Hypoglycemia Prevention in Adults With Type 1 Diabetes Using an Artificial Pancreas

Lead Sponsor:

Marc Breton

Conditions:

Type 1 Diabetes Mellitus

Hypoglycemia

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

This is a randomized crossover trial with 1:1 randomization to the admission sequence of using the Control AP system (rMPC - Naïve Model Predictive Control) vs. Experimental AP system (EnMPC - Ensembl...

Detailed Description

Exercise remains a challenge to AP systems; more specifically, by the time exercise is detected it is often too late to avoid hypoglycemia without the ingestion of rapid carbohydrates or the use of re...

Eligibility Criteria

Inclusion

  • Age ≥18 and ≤65 years
  • Clinical diagnosis of Type 1 Diabetes for at least one year
  • Currently using an insulin pump for at least 6 months
  • Uses insulin parameters such as carbohydrate ratio and correction factors consistently on their insulin pump in order to dose insulin for meals or corrections
  • Access to internet and willingness to upload data during the study
  • Willingness to be physically active for at least 30 minutes per day at least 4 times per week
  • Willingness to perform the required exercise regimen during Data Collection Period
  • Willingness to not perform regular exercise outside of the study-regimented exercise window
  • For females, not currently pregnant or breastfeeding. If a female is of child-bearing potential and sexually active, she must agree to use a form of contraception to prevent pregnancy while participating in the study.
  • An understanding and willingness to follow the protocol and sign informed consent.

Exclusion

  • History of diabetic ketoacidosis (DKA) in the 12 months prior to enrollment.
  • Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment.
  • Pregnancy or intent to become pregnant during the trial.
  • Currently being treated for a seizure disorder
  • Coronary artery disease or heart failure, unless written clearance is received from a cardiologist or primary care provider and documentation of a negative stress test within the year
  • History of cardiac arrhythmia (except for benign premature atrial contractions and benign premature ventricular contractions which are permitted)
  • Clinically significant electrocardiogram (ECG) at time of Screening, as interpreted by the study medical physician.
  • Use of non-insulin glucose-lowering agent (including GLP-1 agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals) with the exception of participants who have been on a stable dose of Metformin for at least 3 months.
  • A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:
  • Inpatient psychiatric treatment in the past 6 months
  • Presence of a known adrenal disorder
  • Abnormal liver function test results (Transaminase \>2 times the upper limit of normal); testing required for subjects taking medications known to affect liver function or with diseases known to affect liver function
  • Uncontrolled thyroid disease
  • Use of an automated insulin delivery mechanism that is not FDA approved during the data collection phase
  • Use of an automated insulin delivery mechanism that is not downloadable by the subject or study team
  • Inability to be physically active for at least 30 minutes per day for at least 4 times per week
  • Current enrollment in another clinical trial, unless approved by the investigators of both studies or if clinical trial is a non-interventional registry trial.

Key Trial Info

Start Date :

April 12 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 13 2020

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT03859401

Start Date

April 12 2019

End Date

January 13 2020

Last Update

January 18 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Virginia

Charlottesville, Virginia, United States, 22908

Exercise-Induced Hypoglycemia Prevention in Adults With Type 1 Diabetes Using an Artificial Pancreas | DecenTrialz